📋 Pep IQ provides independent reference information for educational purposes only. Nothing here constitutes medical advice or treatment recommendation. All compounds require individual assessment. Consult a qualified physician before considering any peptide protocol.
GH Secretagogues · Ghrelin Mimetics Research Compounds Older Generation GHRPs

GHRP-2
& GHRP-6

Growth Hormone Releasing Peptide-2 · Pralmorelin · GHRP-6 · His-DTrp-Ala-Trp-DPhe-Lys

"The originals. Before ipamorelin, GHRP-2 and GHRP-6 defined the GH secretagogue category. More powerful than ipamorelin — and less selective. Understanding why they were replaced clarifies everything about what ipamorelin does differently."

GHRP-2
More potent · raises cortisol · minimal hunger
GHRP-6
Strong GH · significant hunger stimulation
Receptor
GHSR-1a (ghrelin receptor)
FDA Status
Not approved · Research only
WADA
Prohibited
Protocol summary
GHRP-2 dose
100–300 mcg, 2–3× daily
GHRP-6 dose
100–300 mcg, 2–3× daily
Cycle
8–16 weeks, then 4 weeks off
Stack with
GHRH analog (CJC/Mod-GRF)
How we read the evidence
Original GH-secretagogue class · approved in Japan as diagnostic agent · cycling is not optional · receptor desensitises with continuous use
Animal evidence

First-generation ghrelin mimetics characterised by Cyril Bowers and colleagues in the 1980s. GHRP-2 (Pralmorelin) and GHRP-6 are six-amino-acid peptides that bind the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons, triggering pulsatile GH release. Animal work established the dose-response curve, the hard ceiling at receptor saturation, and the rapid tachyphylaxis with continuous dosing. Cytoprotective effects (cardiac, gastric) reported across multiple animal models.

Community & clinical practice

Community protocols converge on 100–300 mcg SubQ 2–3 times daily on an empty stomach, with the bedtime dose being most important (synergises with the natural nocturnal GH surge). Always paired with a GHRH analog — CJC-1295 no-DAC or Mod-GRF 1-29 — because the GHRP+GHRH synergy is the foundational principle of the modern GH-secretagogue protocol. Cycle 8–16 weeks then break 4–8 weeks. Cycling is required, not optional — chronic continuous use causes GHS-R1a downregulation and the response stops. GHRP-6 has substantial appetite signal (used deliberately in muscle-gain phases); GHRP-2 has milder appetite effect. Hexarelin is more potent but causes the fastest tachyphylaxis. Ipamorelin is the cleanest of the class with minimal cortisol/prolactin spillover.

Human trial data

Phase 1/2 pharmacokinetic and pharmacodynamic studies have been published (European Journal of Endocrinology 1997, European Journal of Pharmaceutical Sciences 2013). GHRP-2 (Pralmorelin) has been used as a diagnostic agent in Japan for GH deficiency assessment. No therapeutic FDA approval pathway has been pursued. Differential pulsatile secretagogue control studies (American Physiological Society 2013) clarified how GHRP-2, GHRH, and somatostatin interact to determine pulsatile GH secretion, with testosterone modulating the interaction.

Regulatory status

Not FDA-approved for therapeutic use. GHRP-2 (Pralmorelin) approved in Japan as a diagnostic agent only. WADA-banned for tested athletes. Sourcing via research-peptide vendors. Side effects to monitor: cortisol elevation (more for GHRP-6 than GHRP-2/Ipamorelin), prolactin (less concerning at standard doses), insulin sensitivity reduction with sustained GH/IGF-1 elevation, and appetite (significant with GHRP-6, mild with GHRP-2).

Convergence

The GHRP class works mechanistically and has decades of pharmacological validation, but cycling is required for the protocol to keep working — receptor downregulation is the primary failure mode of users running these continuously. Standard protocol: 100–300 mcg 2–3× daily paired with a GHRH analog, 8–16 weeks on, 4–8 weeks off. Ipamorelin is the cleanest version, GHRP-2 the standard performance choice, GHRP-6 only when appetite stimulation is wanted. Monitor IGF-1 and fasting glucose during extended cycles. No long-term human safety data for repeated cycling beyond the typical pharma development timeframe.

Community-reported
100–300 mcg SubQ · 2–3× daily
Pre-meal pulses common; paired with GHRH analog
Origin & Background

The first generation GH secretagogues

GHRP-2 and GHRP-6 are synthetic hexapeptides that were among the first ghrelin receptor (GHSR-1a) agonists developed for research into growth hormone secretion. They were synthesised in the 1980s and 1990s as part of the effort to understand how ghrelin — the stomach's hunger hormone — stimulates GH release from the pituitary independently of GHRH.

Both peptides bind the GHSR-1a receptor with high affinity and produce substantial GH release. In multiple clinical studies, GHRP-2 was found to be more potent than GHRP-6 for GH stimulation. However, both produce side effects that ipamorelin — specifically designed to be selective — largely avoids. This is the key reason ipamorelin overtook them as the preferred GHRP in clinical practice: ipamorelin produces comparable or greater GH release with a much cleaner side effect profile.

Despite being superseded by ipamorelin in most clinic protocols, GHRP-2 and GHRP-6 remain widely used in the biohacking community — partly because they are cheaper, partly because the hunger stimulation from GHRP-6 is considered a feature by some users in bulking phases, and partly because the community established protocols around them before ipamorelin became widely available.

Why GHRP-2 and GHRP-6 still matter: Understanding them clarifies the entire GHRP category. They demonstrate that ghrelin receptor agonism is the mechanism — and that selectivity matters enormously within that mechanism. GHRP-2 also holds the distinction of being studied in a 47-fold GH pulse amplification study when combined with GHRH, establishing the synergistic dual-receptor principle that underlies all modern GH secretagogue combination protocols.

Science & Mechanism

Non-selective ghrelin receptor activation

GHRP-2 vs GHRP-6 vs Ipamorelin

1
GHSR-1a binding (all three): GHRP-2, GHRP-6, and ipamorelin all bind the ghrelin receptor (GHSR-1a) on pituitary somatotrophs, activating phospholipase C and calcium signalling to trigger GH release. This is the shared mechanism.
2
GHRP-2 — potent but cortisol-raising: GHRP-2 produces strong GH release (up to 47x baseline in synergy with GHRH) but also stimulates ACTH and cortisol release. Elevated cortisol is catabolic — counterproductive in the anabolic context where GH secretagogues are typically used. Also mildly raises prolactin.
3
GHRP-6 — GH plus hunger: Produces significant GH release but also strongly activates ghrelin's primary physiological role — stimulating hunger via the hypothalamus. Users report intense food cravings 20–45 minutes post-injection. This hunger stimulation is mediated by the same GHSR-1a receptor, demonstrating that the receptor has multiple downstream effects.
4
Ipamorelin — selective GHSR agonism: Raun et al. (1998) established that ipamorelin activates GHSR-1a without stimulating cortisol, ACTH, prolactin, or significant hunger. This selectivity is the result of different binding characteristics at the receptor — ipamorelin activates the GH-releasing pathway without triggering the off-target effects of the older GHRPs.
5
GHRH synergy (all three): When any GHRP is combined with a GHRH analogue (Mod-GRF, sermorelin, CJC-1295), GH release is synergistically amplified 3–5x (ipamorelin) to 47x (GHRP-2 at high dose). This dual-receptor activation is the basis for all combination GH secretagogue protocols.
GHRP-2 Profile
GH potencyVery high
Cortisol↑ Raised
Prolactin↑ Mildly raised
HungerMild increase
Typical dose100–300mcg SubQ
Half-life~15–60 minutes
GHRP-6 Profile
GH potencyHigh
Cortisol↑ Mildly raised
Prolactin↑ Raised
HungerStrong — "the hunger GHRP"
Typical dose100–300mcg SubQ
Half-life~15–60 minutes
Benefits & Evidence

What the data shows

📈
GH release — among the most potent available
GHRP-2 in combination with GHRH produced 47-fold increase in pulsatile GH secretion in hypogonadal men (Sinha et al.). Both compounds produce robust GH stimulation with a well-established mechanism. The raw GH potency exceeds ipamorelin at equivalent doses.
● Moderate — clinical studies exist, no Phase III
💪
Body composition (via GH/IGF-1)
The downstream body composition effects of elevated GH — lean mass increase, lipolysis, improved recovery — apply to all GHRPs. GHRP-6's hunger stimulation may support caloric surplus for muscle building in bulking phases.
● Moderate — extrapolated from GH literature
🔬
Research utility — diagnostic GH testing
GHRP-2 is used clinically as a GH stimulation test agent in some countries for diagnosing GH deficiency — a legitimate diagnostic application with a clear evidence base. Not a consumer application but demonstrates the clinical seriousness of the compound.
● Strong — diagnostic use with clinical evidence
Safety First

Risks & considerations

⚠️
The main safety concern unique to GHRP-2 and GHRP-6 is their non-selectivity. The cortisol elevation from GHRP-2 is catabolic — counterproductive for muscle building and potentially problematic with chronic use. The prolactin elevation from GHRP-6 can suppress testosterone and libido. Neither effect occurs with ipamorelin. These are not theoretical risks — they are documented in the clinical literature and reported consistently by users.
Moderate
Cortisol elevation (GHRP-2) — ACTH stimulation raises cortisol. Chronically elevated cortisol is catabolic, suppresses immune function, and contributes to anxiety and poor sleep. The very effect that makes GHRP-2 less desirable than ipamorelin for regular use.
Moderate
Prolactin elevation (GHRP-6) — raises prolactin which can suppress testosterone and libido in men and cause menstrual irregularities in women with chronic use at higher doses.
Mild
Intense hunger (GHRP-6) — the ghrelin receptor hunger signal is strong and predictable within 30 minutes of injection. A feature in bulking contexts, a significant problem when trying to maintain caloric control.
Moderate
Water retention and IGF-1 elevation — same as ipamorelin and other GHRPs. Monitor IGF-1.
Serious
Contraindicated in active malignancy — same as all GH-axis compounds.

⚠ Key Warnings

For body composition goals, ipamorelin is strictly preferable to both GHRP-2 and GHRP-6. It produces comparable GH release without cortisol or prolactin elevation. The only reason to use GHRP-2 or GHRP-6 over ipamorelin is cost or specific use cases (GHRP-6 hunger for bulking).
Monitor cortisol if using GHRP-2 regularly — particularly relevant for people who are already under chronic stress or running high-intensity training programmes.
WADA prohibited at all times for competitive athletes.
Inject fasted — same insulin-GH interaction applies as with all GHRPs.
Honest Assessment

Editor's summary

GHRP-2 and GHRP-6 are historically important — they established the ghrelin receptor as a viable GH stimulation target and defined the GHRP category. The 47-fold GH synergy study with GHRP-2 and GHRH is foundational research that still informs combination protocols today.

In current practice, both have been largely superseded by ipamorelin for most applications. The cortisol elevation of GHRP-2 and the prolactin elevation and hunger stimulation of GHRP-6 are pharmacological downsides that ipamorelin was specifically engineered to avoid. The GH output is comparable or greater — but at a cost that generally isn't worth paying when ipamorelin is available.

The exceptions: GHRP-6 for deliberate appetite augmentation in caloric surplus phases, GHRP-2 for maximum GH output when the cortisol side effect is acceptable, or budget-constrained situations where GHRP-2/6 cost significantly less than ipamorelin.

Verdict
"The first generation — powerful, imperfect, and ultimately superseded by ipamorelin for most purposes. Still useful in specific contexts (GHRP-6 for appetite, GHRP-2 for maximum GH potency). Understanding them explains why ipamorelin exists and why selectivity matters in peptide pharmacology."